FDA says Beta Bionics' iLet Bionic Pancreas system had quality-system failures, including ignored complaints of severe hypoglycemia and diabetic ketoacidosis.
What happened
FDA inspected Beta Bionics' Irvine, California site from June 9 to June 26, 2025, and reviewed complaint records from June 2023 through June 2025. Investigators found the company did not open corrective actions for complaints of device malfunctions tied to serious harm, did not investigate hundreds of complaints about leaking insulin cartridges and bent cannulas, and did not feed post-market safety data into its risk analysis. FDA reviewed the company's responses of July 18, August 29, and October 29, 2025 and judged them not adequate.
What FDA found
The company did not properly analyze complaint data or open corrective and preventive actions (CAPA, a formal fix-and-prevent process) for malfunctions linked to diabetic ketoacidosis and severe hypoglycemia, and closed 56 complaints without acting or explaining why.
21 CFR 820.100(a)The company's risk analysis for the iLet system was not kept current, leaving out post-market hazards such as failed circuit boards, involuntary meal announcements, and leaking cartridges.
21 CFR 820.30(g)The company closed complaints without investigation, including 31 leaking cartridge or connector complaints and 21 bent cannula complaints tied to diabetic ketoacidosis, and did not ask for failed infusion sets to be returned.
21 CFR 820.198(a)The company did not properly control nonconforming product: it found 61 of its printed circuit board mainboards failing a test, did not document the supplier investigation, and did not issue a supplier corrective action.
21 CFR 820.90(a)FDA states the devices are misbranded because the firm failed or refused to furnish required material or information under the Medical Device Reporting requirements (the rules for telling FDA about device-related deaths and serious injuries).
21 U.S.C. ยง 352(t)(2)
What FDA wants
FDA tells Beta Bionics to correct the cited violations and says the company's responses so far are not adequate. FDA asks the firm to continue sending updates on its corrective actions, including the new complaint handling system and the retrospective complaint review.
Who should pay attention
- makers of software-controlled insulin dosing devices
- companies that buy circuit board assemblies or infusion sets from suppliers
- quality teams that decide when complaints must be escalated to CAPA
This is a summary. Read the original letter on fda.gov.